Cambridge-based Genzyme Corp., which has significant operations in Central Massachusetts, has completed its acquisition of a multiple sclerosis therapy and two cancer drugs from Bayer HealthCare.
The multiple sclerosis drug, branded as Campath, is currently in phase III clinical trials.
The cancer drugs are known as Fludara and Leukine. Genzyme has acquired the worldwide marketing and distribution rights for the two drugs.
Genzyme will make no upfront payments to Bayer. In exchange for the rights to the drugs, Genzyme will make payments based on revenues. Genzyme will also acquire a new Leukine manufacturing facility upon FDA approval of the plant, which is expected in 2010.
